Author:
Clarke Jeffrey M.,Gu Lin,Wang Xiaofei F.,Stinchcombe Thomas E.,Stevenson Marvaretta M.,Ramalingam Sundhar,Shariff Afreen,Garst Jennifer,Nixon Andrew B.,Antonia Scott J.,Crawford Jeffrey,Ready Neal E.
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference24 articles.
1. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial;Sezer;Lancet,2021
2. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC;Herbst;N Engl J Med,2020
3. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016
4. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer;Paz-Ares;N Engl J Med,2018
5. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N Engl J Med,2018
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献